Literature DB >> 166089

Inhibition by somatostatin of ACTH secretion in Nelson's syndrome.

J B Tyrrell, M Lorenzi, J E Gerich, P H Forsham.   

Abstract

Somatostatin (GHIF), when administered as a 1-hr infusion (500 mug/hr) to 5 patients with Nelson's Syndrome;resulted in a sustained, progressive fall in plasma ACTH in each patient to 40% to 71% of basal values with a return toward initail levels after cessation of the infusion. The meanreduction in plasma ADTH was 48% (p less than 0.005). These finding suggest that GHIF receptors not fuctional or present in normal pituitary tissue are present in ACTH-producing pituitary tumors.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 166089     DOI: 10.1210/jcem-40-6-1125

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  22 in total

1.  Diagnosis and treatment of Cushing's syndrome. Cushing's syndrome: current clinical problems, symposium. Padova, October 19-20, 1990.

Authors: 
Journal:  J Endocrinol Invest       Date:  1992-03       Impact factor: 4.256

2.  Constitutive somatostatin receptor activity determines tonic pituitary cell response.

Authors:  Anat Ben-Shlomo; Cuiqi Zhou; Oxana Pichurin; Vera Chesnokova; Ning-Ai Liu; Michael D Culler; Shlomo Melmed
Journal:  Mol Endocrinol       Date:  2009-01-08

3.  Dynamics of calcium-induced insulin release.

Authors:  G Devis; G Somers; W J Malaisse
Journal:  Diabetologia       Date:  1977-09       Impact factor: 10.122

4.  Somatostatin inhibits multireceptor stimulation of cyclic AMP formation and corticotropin secretion in mouse pituitary tumor cells.

Authors:  S Heisler; T D Reisine; V Y Hook; J Axelrod
Journal:  Proc Natl Acad Sci U S A       Date:  1982-11       Impact factor: 11.205

Review 5.  The role of somatostatin analogs in Cushing's disease.

Authors:  Joost van der Hoek; Steven W J Lamberts; Leo J Hofland
Journal:  Pituitary       Date:  2004       Impact factor: 4.107

6.  Long-term treatment of Nelson's syndrome by octreotide: a case report.

Authors:  L Petrini; M Gasperi; R Pilosu; A Marcello; E Martino
Journal:  J Endocrinol Invest       Date:  1994-02       Impact factor: 4.256

7.  The effects of octreotide in a patient with Nelson's syndrome.

Authors:  F Kelestimur; C Utas; O Ozbakir; A Selçuklu; O Kandemir; N Ozcan
Journal:  Postgrad Med J       Date:  1996-01       Impact factor: 2.401

8.  Medical treatment of Cushing's disease: Overview and recent findings.

Authors:  Stephanie Smooke Praw; Anthony P Heaney
Journal:  Int J Gen Med       Date:  2009-12-29

9.  Treatment of Cushing disease: overview and recent findings.

Authors:  Tatiana Mancini; Teresa Porcelli; Andrea Giustina
Journal:  Ther Clin Risk Manag       Date:  2010-10-21       Impact factor: 2.423

Review 10.  Future treatment strategies of aggressive pituitary tumors.

Authors:  Steven W J Lamberts; Leo J Hofland
Journal:  Pituitary       Date:  2009       Impact factor: 4.107

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.